Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPPG2-TSL-DOX plus Regional Hyperthermia in Advanced Soft Tissue Sarcoma
NCT05858710Phase 1Completed
- Sponsor
- Thermosome
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TSL-DOX in soft tissue sarcoma (STS), sponsored by Thermosome. Primary endpoints: Maximum Tolerated Dose up to 14 months and Highest Tolerated Dose up to 14 months. Started Apr 2023; status: completed.
02
Drugs
TSL-DOX
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05858710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858710.